ALA-PDT治疗轻中度宫颈上皮内瘤样病变伴高危型HPV感染临床观察

发布时间：2018-11-15 07:06

【摘要】：目的评价5-氨基酮戊酸光动力疗法(ALA-PDT)治疗宫颈上皮内瘤样病变(CIN)1/2伴高危型人乳头状瘤病毒(HR-HPV)感染的临床疗效和安全性,探讨ALA治疗的最佳浓度。方法将入选的120例CIN1/2伴HR-HPV感染患者随机分为4组,分别予ALA浓度为20%,10%和5%及安慰剂治疗。3~6个月后根据皮肤活检、巴氏涂片和HPV检测结果评估治疗效果。结果治疗3~6个月后,安慰剂组与不同浓度ALA组中CIN1患者的有效率差异均无统计学意义(不同浓度ALA组vs安慰剂组,P均0.05),20%ALA组中CIN2患者的有效率显著高于安慰剂组患者的有效率,且差异有统计学意义(56.25%vs 95.00%,P0.01)。治疗6个月后,20%ALA组中CIN2患者HPV 16/18阴转率为85.00%,安慰剂组CIN2患者阴转率为31.25%,差异有统计学意义(P0.01)。结论 20%ALAPDT可以治疗CIN2,还可以清除HR-HPV。
[Abstract]:Objective to evaluate the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of cervical intraepithelial neoplasia (CIN) 1 / 2) with high-risk human papillomavirus (HR-HPV) infection, and to explore the optimal concentration of ALA. Methods one hundred and twenty CIN1/2 patients with HR-HPV infection were randomly divided into 4 groups and treated with 10% and 5% ALA and placebo respectively. After 3 ~ 6 months, the results of skin biopsy, pasteurization smear and HPV were used to evaluate the therapeutic effect. Results after 3 ~ 6 months of treatment, there was no significant difference in the effective rate of CIN1 between the placebo group and the different concentration ALA group (vs placebo group with different ALA concentration, P 0.05). The effective rate of CIN2 in 20%ALA group was significantly higher than that in placebo group, and the difference was statistically significant (56.25%vs 95.00 P0.01). After 6 months of treatment, the negative conversion rate of HPV 16 / 18 in CIN2 group was 85.00 in 20%ALA group and 31.2550 in placebo group (P0.01). Conclusion 20%ALAPDT can treat CIN2, and eliminate HR-HPV..
【作者单位】：山西大同大学医学院微生物与免疫学研究所;山西大同大学医学院解剖教研室;大同市第三人民医院皮肤科;
【基金】：大同市科技攻关项目(2016101)
【分类号】：R737.33

【相似文献】